Literature DB >> 28829409

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model.

Dimitra Kotsougiani1, Caroline A Hundepool1, Joost I Willems1, Patricia Friedrich1, Alexander Y Shin1, Allen T Bishop2.   

Abstract

Segmental bone loss resulting from trauma, infection malignancy and congenital anomaly remains a major reconstructive challenge. Current therapeutic options have significant risk of failure and substantial morbidity. Use of bone vascularized composite allotransplantation (VCA) would offer both a close match of resected bone size and shape and the healing and remodeling potential of living bone. At present, life-long drug immunosuppression (IS) is required. Organ toxicity, opportunistic infection and neoplasm risks are of concern to treat such non-lethal indications. We have previously demonstrated that bone and joint VCA viability may be maintained in rats and rabbits without the need of long-term-immunosuppression by implantation of recipient derived vessels within the VCA. It generates an autogenous, neoangiogenic circulation with measurable flow and active bone remodeling, requiring only 2 weeks of IS. As small animals differ from man substantially in anatomy, bone physiology and immunology, we have developed a porcine bone VCA model to evaluate this technique before clinical application is undertaken. Miniature swine are currently widely used for allotransplantation research, given their immunologic, anatomic, physiologic and size similarities to man. Here, we describe a new porcine orthotopic tibial bone VCA model to test the role of autogenous surgical angiogenesis to maintain VCA viability. The model reconstructs segmental tibial bone defects using size- and shape-matched allogeneic tibial bone segments, transplanted across a major swine leukocyte antigen (SLA) mismatch in Yucatan miniature swine. Nutrient vessel repair and implantation of recipient derived autogenous vessels into the medullary canal of allogeneic tibial bone segments is performed in combination with simultaneous short-term IS. This permits a neoangiogenic autogenous circulation to develop from the implanted tissue, maintaining flow through the allogeneic nutrient vessels for a short time. Once established, the new autogenous circulation maintains bone viability following cessation of drug therapy and subsequent nutrient vessel thrombosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28829409      PMCID: PMC5614272          DOI: 10.3791/55238

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  38 in total

1.  Radiological and histological analysis of cortical allografts: an experimental study in sheep femora.

Authors:  Hirofumi Taira; Jose Moreno; Purificacion Ripalda; Francisco Forriol
Journal:  Arch Orthop Trauma Surg       Date:  2004-04-02       Impact factor: 3.067

2.  Vascularized composite allograft tolerance across MHC barriers in a large animal model.

Authors:  D A Leonard; J M Kurtz; C Mallard; A Albritton; R Duran-Struuck; E A Farkash; R Crepeau; A Matar; B M Horner; M A Randolph; D H Sachs; C A Huang; C L Cetrulo
Journal:  Am J Transplant       Date:  2014-01-09       Impact factor: 8.086

3.  Detection of host cells following sex-mismatched bone marrow transplantation by fluorescent in situ hybridization with a Y-chromosome specific probe.

Authors:  H van Dekken; A Hagenbeek; J G Bauman
Journal:  Leukemia       Date:  1989-10       Impact factor: 11.528

4.  Transplantation of a vascularized rabbit femoral diaphyseal segment: mechanical and histologic properties of a new living bone transplantation model.

Authors:  Goetz A Giessler; Mark Zobitz; Patricia F Friedrich; Allen T Bishop
Journal:  Microsurgery       Date:  2008       Impact factor: 2.425

5.  Face transplant: long-term follow-up and results of a prospective open study.

Authors:  Laurent Lantieri; Philippe Grimbert; Nicolas Ortonne; Caroline Suberbielle; Dominique Bories; Salvador Gil-Vernet; Cédric Lemogne; Frank Bellivier; Jean Pascal Lefaucheur; Nathaniel Schaffer; Fréderic Martin; Jean Paul Meningaud; Pierre Wolkenstein; Mikael Hivelin
Journal:  Lancet       Date:  2016-08-25       Impact factor: 79.321

6.  Nomenclature for factors of the SLA system, update 2008.

Authors:  C-S Ho; J K Lunney; A Ando; C Rogel-Gaillard; J-H Lee; L B Schook; D M Smith
Journal:  Tissue Antigens       Date:  2009-04

7.  Repopulation of vascularized bone allotransplants with recipient-derived cells: detection by laser capture microdissection and real-time PCR.

Authors:  Michael Pelzer; Mikko Larsen; Patricia F Friedrich; Ross A Aleff; Allen T Bishop
Journal:  J Orthop Res       Date:  2009-11       Impact factor: 3.494

8.  Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine.

Authors:  R Büttemeyer; N F Jones; Z Min; U Rao
Journal:  Plast Reconstr Surg       Date:  1996-01       Impact factor: 4.730

9.  Use of the Ilizarov technique after a free microvascular muscle flap transplantation in massive trauma of the lower leg.

Authors:  E Tukiainen; S Asko-Seljavaara
Journal:  Clin Orthop Relat Res       Date:  1993-12       Impact factor: 4.176

Review 10.  Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF.

Authors:  Ernestina Schipani; Christa Maes; Geert Carmeliet; Gregg L Semenza
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

View more
  2 in total

1.  Neo-Angiogenesis, Transplant Viability, and Molecular Analyses of Vascularized Bone Allotransplantation Surgery in a Large Animal Model.

Authors:  Rudolph H Houben; Roman Thaler; Dimitra Kotsougiani; Patricia F Friedrich; Alexander Y Shin; Andre J van Wijnen; Allen T Bishop
Journal:  J Orthop Res       Date:  2019-10-06       Impact factor: 3.494

2.  Transplant chimerism in porcine structural vascularized bone allotransplants.

Authors:  Rudolph H Houben; Ross A Aleff; Patricia F Friedrich; Alexander Y Shin; Eric D Wieben; Andre J van Wijnen; Allen T Bishop
Journal:  Gene       Date:  2020-03-26       Impact factor: 3.688

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.